Literature DB >> 23804564

Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.

Jiong Wang1, Dongge Li1, Robert A Bambara2, Carrie Dykes1.   

Abstract

Previous work by our group showed that human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) containing non-nucleoside RT inhibitor (NNRTI) drug resistance mutations has defects in RNase H activity as well as reduced amounts of RT protein in virions. These deficits correlate with replication fitness in the absence of NNRTIs. Viruses with the mutant combination K101E+G190S replicated better in the presence of NNRTIs than in the absence of drug. Stimulation of virus growth by NNRTIs occurred during the early steps of the virus life cycle and was modulated by the RT backbone sequence in which the resistance mutations arose. We wanted to determine what effects RT backbone sequence would have on RT content and polymerization and RNase H activities in the absence of NNRTIs. We compared a NL4-3 RT with K101E+G190S to a patient-isolate RT sequence D10 with K101E+G190S. We show here that, unlike the NL4-3 backbone, the D10 backbone sequence decreased the RNA-dependent DNA polymerization activity of purified recombinant RT compared to WT. In contrast, RTs with the D10 backbone had increased RNase H activity compared to WT and K101E+G190S in the NL4-3 backbone. D10 virions also had increased amounts of RT compared to K101E+G190S in the NL4-3 backbone. We conclude that the backbone sequence of RT can alter the activities of the NNRTI drug-resistant mutant K101E+G190S, and that identification of the amino acids responsible will aid in understanding the mechanism by which NNRTI drug-resistant mutants alter fitness and NNRTIs stimulate HIV-1 virus replication.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23804564      PMCID: PMC3785032          DOI: 10.1099/vir.0.054999-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  63 in total

Review 1.  Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target.

Authors:  S Srivastava; N Sluis-Cremer; G Tachedjian
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

2.  Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity.

Authors:  Suhman Chung; Jennifer T Miller; Barry C Johnson; Stephen H Hughes; Stuart F J Le Grice
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

3.  Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.

Authors:  Gilberto Betancor; Maria C Puertas; María Nevot; César Garriga; Miguel A Martínez; Javier Martinez-Picado; Luis Menéndez-Arias
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

4.  Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.

Authors:  Soumi Gupta; Johan Vingerhoets; Signe Fransen; Lotke Tambuyzer; Hilde Azijn; Arne Frantzell; Roger Paredes; Eoin Coakley; Steven Nijs; Bonaventura Clotet; Christos J Petropoulos; Jonathan Schapiro; Wei Huang; Gaston Picchio
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

5.  Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.

Authors:  L Vergne; M Peeters; E Mpoudi-Ngole; A Bourgeois; F Liegeois; C Toure-Kane; S Mboup; C Mulanga-Kabeya; E Saman; J Jourdan; J Reynes; E Delaporte
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

6.  High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance.

Authors:  Lucía Pérez-Alvarez; Rocío Carmona; Mercedes Muñoz; Elena Delgado; Michael M Thomson; Gerardo Contreras; José D Pedreira; Rafael Rodríguez Real; Elena Vázquez de Parga; Leandro Medrano; José Antonio Taboada; Rafael Nájera
Journal:  Antivir Ther       Date:  2003-08

7.  Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

Authors:  Krista A Delviks-Frankenberry; Renan B Lengruber; Andre F Santos; Jussara M Silveira; Marcelo A Soares; Mary F Kearney; Frank Maldarelli; Vinay K Pathak
Journal:  Virology       Date:  2012-10-13       Impact factor: 3.616

8.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism.

Authors:  B Chesebro; K Wehrly; J Nishio; S Perryman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

9.  Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.

Authors:  Martin Stürmer; Schlomo Staszewski; Hans-Wilhelm Doerr; Brendan Larder; Stuart Bloor; Kurt Hertogs
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Frank Maldarelli; Saiki Hase; Yutaka Takebe; Vinay K Pathak
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

View more
  1 in total

1.  The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.

Authors:  Yuncong Wang; Hui Xing; Lingjie Liao; Zhe Wang; Bin Su; Quanbi Zhao; Yi Feng; Pengfei Ma; Jia Liu; Jianjun Wu; Yuhua Ruan; Yiming Shao
Journal:  AIDS Res Ther       Date:  2014-11-21       Impact factor: 2.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.